A Real-World Study of CGRP Monoclonal Antibodies for Migraine: Long-Term Effectiveness and Treatment Adherence - PubMed

4 days ago

CGRP monoclonal antibodies (mAbs) show long-term effectiveness in reducing migraine frequency.
The study included 307 migraine patients in Japan treated with erenumab, galcanezumab, or fremanezumab for ≥3 months.
≥50% responder rates increased over time: 45.9% at 3 months, 57.0% at 6 months, 63.6% at 12 months, and 71.0% at 24 months.
Adverse events were mild and occurred in 12.6% of patients.
Early responders had lower baseline migraine days (MMDs) and Migraine Disability Assessment (MIDAS) scores.
Nonresponders had higher baseline MMDs, MIDAS scores, and higher rates of medication overuse headache (MOH) and psychiatric disorders.
Late and ultralate responders had higher baseline MMDs, MIDAS scores, and prior preventive failures.
Treatment continuation rates were 68.3% at 12 months, 58.0% at 18 months, and 50.6% at 24 months.
Effectiveness was similar across the three CGRP mAbs.

Hasty Briefsbeta